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In healthy humans, self-reactive antibodies are 
removed from the B cell repertoire during the 
transition from early immature to immature 
B cells in the bone marrow and from the new 
emigrant to the mature naive B cell compart-
ment in the periphery (1). Untreated systemic 
lupus erythematosus (SLE) patients show de-
fective early B cell tolerance checkpoints and 
therefore accumulate self-reactive and poly-
reactive antibodies in the circulating mature 
  naive B cell compartment (2). Mature naive 
B cells, however, do not secrete antibodies 
and are unlikely to play a direct role in auto-
immune pathology, but they are precursors of 
antibody-secreting cells and therefore aberrant 
self-tolerance in this compartment would pre-
dispose to the development of the high affi   nity 
autoantibodies characteristic of SLE (3, 4).
Immunosuppressive or cytotoxic drugs and 
anti-CD20–mediated B cell depletion can in-
duce long-term remission in patients with SLE 
(5). However, current treatment protocols fre-
quently fail to prevent relapses (5). Further-
more, SLE patients show high levels of serum 
antinuclear antibodies (ANAs) long before the 
onset of disease. The absence of clinical signs 
and symptoms does not necessarily correlate 
with the absence of serum autoantibodies (6). 
Therefore, SLE patients may fail to establish or 
maintain B cell self-tolerance independent of 
their clinical status. Whether this persistent 
  tolerance defect involves early stages in B cell 
development has not been examined.
To determine the status of early B cell tol-
erance in SLE patients in clinical remission, we 
cloned 278 antibodies from mature naive B cells 
from six such patients and tested them for bind-
ing to HEp-2 cell lysates and for polyreactivity 
against a panel of purifi  ed antigens. Here, we 
report that SLE patients in clinical remission 
continue to show increased numbers of self-
  reactive and polyreactive antibodies in the ma-
ture naive B cell compartment, but they have 
fewer B cells expressing these antibodies than 
patients with active disease.
RESULTS AND DISCUSSION
Ig repertoire in SLE patients in remission
To study early B cell tolerance in SLE patients 
during clinical remission, we cloned, expressed, 
and tested antibodies from mature naive B cells 
from six adolescent patients (SLE100CR, 
SLE101CR, SLE122CR, SLE14CR, SLE21CR, 
and SLE33CR; Table I) and compared them 
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to recombinant antibodies cloned from three previously 
published healthy controls (1, 7). Three of the remission pa-
tients described here had been studied at the time of diagnosis 
before any therapeutic intervention (SLE100, SLE101, and 
SLE122; reference 2). All patients met the Revised Criteria of 
the American College of Rheumatology, and their treatment 
is summarized (Table I; reference 2). Remission was defi  ned 
by resolution of clinical symptoms, normalization of laboratory 
fi  ndings, and minimal maintenance therapy, but we did not 
  assay for remission of organ damage (Table I). Samples were 
  obtained at least 3 mo after initial remission, and 278 anti-
bodies were cloned from cDNA libraries created from single 
mature naive B cells purifi  ed on the basis of surface markers 
(CD19+CD10−IgM+CD27−; Tables S1–S6 and Fig. S1, 
which are available at http://www.jem.org/cgi/content/full/
jem.20061446/DC1; reference 8). Sequence analysis con-
fi  rmed that all clones were unrelated and derived from naive 
B cells because they lacked somatic hypermutation (8).
Several diff  erent abnormalities in Ig gene usage have been 
reported for patients with SLE, including bias toward VH3, 
VH4-34, Vκ1, and Vκ4 gene family usage (2, 9). We found 
some of these abnormalities, but no consistent abnormalities 
and no consistent diff  erences between active disease and remis-
sion (Fig. 1). For example, SLE122 initially showed increased 
VH3 gene family representation and unusually short IgH CDR3 
regions, and this pattern remained unchanged after treatment 
(P = 0.948 for VH repertoire, P = 0.454 for IgH CDR3 length), 
but these abnormalities were not found in other patients (Fig. 1, 
A and B; reference 2). In contrast, overrepresentation of Vκ4-1 
was found in active disease in SLE100 and SLE122, but not in 
remission (Fig. 1 C; reference 2). We conclude that there are 
no consistent abnormalities in the IgH or IgL repertoires in SLE 
patients with active disease or in remission, and that although 
some specifi  c features such as long CDR3s are associated with 
increased self-reactivity, they are not predictive.
Autoreactive antibodies
Antibodies reactive with HEp-2 cell lysates as measured in 
ELISA assays (used to detect ANAs, ANA ELISA) are signifi  -
cantly enriched in mature naive B cells from untreated SLE 
patients compared with healthy controls (2). To measure the 
frequency of these antibodies in clinical remission, we tested 
the cloned antibodies in HEp-2 cell ELISA assays and con-
fi  rmed positives by indirect immunofl   uorescence assay on 
HEp-2 cell–coated slides (Fig. 2 A, Tables S1–S6, and Fig. S2, 
which is available at http://www.jem.org/cgi/content/full/
jem.20061446/DC1; references 1 and 2). Although there 
was individual variation, antibodies cloned from mature naive 
B cells from SLE patients in remission remained more 
self-reactive in the HEp-2 ELISA than healthy controls 
Table I.  Patient characteristics
Patient SLE100 SLE101 SLE122 SLE14 SLE21 SLE33
Gender Female Male Female Female Female Female
Age 
at diagnosis
15 yr 15 yr 9 yr 11 yr 17 yr 7 yr
Date 
of diagnosis
10/2002 10/2002 2/2003 11/1998 10/1999 7/2001
Sample SLE100 SLE100CR SLE101 SLE101CR SLE122 SLE122CR SLE14CR SLE21CR SLE33CR
Sample date 10/10/2002 2/12/2004 10/24/2002 3/3/2004 2/22/2003 9/14/2004 6/1/2005 7/21/2005 8/8/2005
Clinical 
course
Arthritis, 
nephritis IIB
Clinical 
remission
Myocarditis, 
nephritis III
Clinical 
remission
Chorea, 
nephritis 
IIB
Clinical 
remission
Clinical 
remission
Clinical 
remission
Clinical 
remission
Therapy None Initially IV steroids 
(stopped  3 mo), 
continues on low 
dose oral steroids, 
PL, aspirin
None Initially IV 
steroids, CPH 
(stopped  10 
mo), continues 
on IV steroids, 
MMF, PL
None Initially IV 
steroids (stopped 
 10 mo), 
continues on 
low dose oral 
steroids
Initially IV CPH 
and steroids 
(stopped  4 
yr), continues 
on PL
Initially IV 
steroids 
(stopped  5 
yr), continues 
on PL
Initially IV 
steroids 
(stopped  3 
yr), continues 
on PL
Hematology L, A, T Normal A Normal L, A Normal Normal Normal Normal
CD19+ cells
×103/ml
284 245 168 378 145 210
Renal Abnormal Normal Abnormal Normal Borderline Normal Normal Normal Normal
ANA ++ + + + +NA NA NA
Serology D, P, Sm, 
RNP
Normal P Normal D Borderline D D Normal Borderline D
ESR, mm/hr 11 25 >120 11 NA 41 50 10 12
Complement Low Normal Low Normal Low Normal Normal Normal Normal
A, anemia; CPH, cyclophosphamide; D, anti–double-stranded DNA antibody; ESR, erythrocyte sedimentation rate; L, lymphopenia; MMF, mycophenolatemofetil; NA, not 
available; P, antiphospholipid antibody; PL, Plaquenil; RNP, anti-RNP antibody; Sm, anti-Smith antibody; T, thrombocytopenia.JEM VOL. 203, October 2, 2006  2257
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(34.25 vs.  19.7%, respectively, P = 0.025; Fig. 2 A; references 
1 and 7). In all three cases where paired samples were avail-
able,  the frequency of HEp-2 reactive antibodies was lower 
in remission than in crisis, but the diff  erence only reached 
statistical signifi  cance in SLE101, who showed near normal 
levels of HEp-2–reactive antibodies in clinical remission 
(22.4% in SLE101CR vs. 19.7% in control, P = 0.710, and 
vs. 50.0% in SLE101, P = 0.009). We conclude that there is 
variability in the HEp-2 reactivity of the antibodies produced 
by mature naive B cells among SLE patients in crisis and re-
mission, but most SLE patients in clinical remission show 
persistent abnormalities in this respect.
Figure 1.  Ig heavy and light chain gene features. The absolute num-
ber of sequences analyzed is indicated in the center of each pie chart. (A) 
VH and JH repertoire. (B) IgH CDR3+ charges and length. Pie charts show 
percent of IgH CDR3s with zero, one, two, or three positively charged 
amino acid (aa) residues. Bar graphs show frequency of IgH CDR3s with 
≤9 aa (white bars), 10–14 aa (light gray bars), 15–19 aa (dark gray bars), 
and 20 aa (black bars). (C) Igκ V and J gene family usage. (D) Igλ V and J 
gene family usage. p-values indicated below the charts or below horizon-
tal lines are in comparison with healthy controls or data obtained from 
the same SLE patient during active disease, respectively (references 1, 2, 
and 7). Values for controls (GO, JB, and JH) and untreated SLE patients 
(SLE100, SLE101, and SLE122) in this and other fi  gures were previously 
published and are shown here for comparison (references 1, 2, and 7).2258  PERSISTANT AUTOANTIBODIES IN SLE REMISSION | Yurasov et al. 
Polyreactivity, i.e., antibody binding to diverse nonrelated 
antigens including self-antigens such as DNA and insulin, is 
another measure of self-reactivity. In normal humans, polyre-
active antibodies comprise  6% of antibodies in the circulat-
ing mature naive B cell compartment, whereas in untreated 
SLE patients, these antibodies account for  31% of the 
  repertoire (1, 2, 7). To determine whether this abnormality 
persists during remission, we tested our collection of remission-
derived antibodies for binding with single-stranded DNA, 
double-stranded DNA, insulin, and LPS (Fig. 2 B).   Although 
the number of polyreactive antibodies varied between indi-
viduals, all but one (SLE101CR) of the clinical remission 
  patients showed signifi   cantly elevated levels (16.7% in 
SLE100CR and SLE122CR, P = 0.083 and 0.041, respec-
tively; 17.8% in SLE21CR, P = 0.033; 19.0% in SLE33CR, 
P = 0.028; and 25.0% in SLE14CR, P < 0.001 vs. 6.2% in 
healthy controls; reference 1). The one patient that diff  ered 
from the rest,  SLE101, had higher than normal levels of 
Figure 2.  Autoreactive antibodies. (A) Pie charts summarize self-
reactivity as measured by HEp-2 cell ELISA and HEp-2 cell immunofl  uo-
rescence assay (Tables S1–S6, Fig. S2, and not depicted) with the number 
of tested antibodies indicated in the center of each pie chart. Graphs 
show HEp-2 cell ELISA results. Red lines show the low positive serum 
control and horizontal lines indicate cutoff OD405 levels for positive reac-
tivity. (B) Polyreactivity was measured by ELISA with single-stranded DNA, 
double-stranded DNA, insulin, and LPS. The frequency of polyreactive 
clones is summarized in the pie charts with the number of tested anti-
bodies indicated in the pie chart centers. Graphs show polyreactivity 
ELISA results. Dotted lines show ED38+ control (references 1 and 29) and 
horizontal lines indicate cutoff OD405 levels for reactivity. p-values indi-
cated below the pie charts or below the horizontal lines are in comparison 
with healthy controls or data obtained from the same SLE patient with 
active disease, respectively (references 1, 2, and 7).JEM VOL. 203, October 2, 2006  2259
BRIEF DEFINITIVE REPORT
  polyreactivity before treatment (25.8%, P = 0.004; reference 2) 
but reverted to normal levels of polyreactivity in clinical 
  remission (3.0% in SLE101CR vs. 6.2% in control, P = 
0.499). The other paired samples showed decreased polyreac-
tivity in remission, but the diff  erence did not reach statistical 
signifi   cance (30.8% in SLE100 and 16.7% in SLE100CR, 
P  = 0.444; 24.4% in SLE122 and 16.7% in SLE122CR, 
P = 0.433). Finally, when all remission samples, including 
SLE101CR, were combined, the overall level of polyreactiv-
ity in the mature naive B cell compartment was signifi  cantly 
greater than in healthy controls (15.5 vs. 6.2%, respectively, 
P = 0.009), but the frequency of polyreactive antibodies in 
clinical remission was signifi  cantly lower than at the time of 
diagnosis (15.5 vs. 31.5%, respectively, P < 0.001; Fig. 2 B).
The abnormalities in early B cell self-tolerance in active 
SLE might be secondary to disease activity per se because lym-
phopenia and mediators of acute infl  ammation such as type I 
IFNs and TNF-α can directly alter B cell development in vivo 
(10–12). Indeed, we found a decrease in the number of HEp-
2–reactive and polyreactive antibodies expressed by circulating 
mature naive B cells during remission. However, despite nor-
mal numbers of circulating lymphoid and myeloid cells (Table I), 
the majority of patients in clinical remission continued to show 
persistent abnormalities in antibody tolerance in the mature 
naive B cell compartment, suggesting that defects in early tol-
erance defects are in part independent of active disease.
Ig gene usage and antibody self-reactivity
Primary Ig gene rearrangements frequently involve 3′ Vκ genes 
and 5′ Jκ genes (13–15). This allows for replacement of self-
  reactive antibodies by secondary recombination between 5′ Vκ 
genes and 3′ Jκ genes during receptor editing (13–15). Abnor-
malities in IgL chain receptor editing based on sequence analy-
ses have been reported in patients with autoimmune diseases 
including SLE (9, 16, 17), but these reports did not discriminate 
between patients with active disease and patients in clinical 
  remission. To determine whether receptor editing associated 
genomic alterations occurs in the Igκ locus in SLE patients, we 
analyzed the Vκ and Jκ usage of self-reactive versus nonself-
  reactive antibodies (Fig. 3). Vκ genes were divided into four 
groups according to their 5′ to 3′ orientation in the Igκ locus 
(VκA–VκD). Jκ genes were grouped into 5′ (Jκ1/2) and 3′ 
(Jκ3/4/5) genes. In healthy controls, few self-reactive or poly-
reactive antibodies were present in the mature naive B cell 
compartment (1, 7), and there was no apparent diff  erence in 
Jκ usage between self-reactive and nonself-reactive antibodies 
(0.2 and 0.4, respectively; Fig. 3 A). In contrast, untreated SLE 
patients with active disease showed high levels of self-reactive 
antibodies that used 5′ Jκ genes (ratio of self-reactive/  nonself-
reactive: 1.5 for SLE100, P = 0.006; 1.4 for SLE101, P = 0.01; 
and 1.3 for SLE122, P = 0.013 when compared with healthy 
controls; references 1 and 7) and a variable level of self-reactive 
antibodies that used 3′ Jκ genes (0.3 for SLE100, P = 1.0; 0.4 
for SLE101, P = 1.0; and 1.5 for SLE122, P = 0.047).  However, 
SLE patients in remission resembled healthy controls in terms of 
frequency of self-reactive antibodies that used 5′ Jκ genes and 
were signifi  cantly diff  erent from patients with active disease 
(0.4 in total SLECR vs. 1.4 in total SLE, P = 0.001; 0.4 in total 
SLECR vs. 0.2 in controls, P = 0.229; references 1, 2, and 7). 
We found a signifi  cant bias toward 3′ Vκ gene usage in 
Figure 3.  Ig gene usage and antibody self-reactivity of mature 
naive B cells from SLE patients in clinical remission. (A) Jκ genes 
were grouped according to their 5′ (Jκ1) and 3′ (Jκ3/4/5) position, and 
the proportion of self-reactive (black) versus nonself-reactive antibodies 
(white) is indicated as a bar graph for each group with the ratio of self-
reactive versus nonself-reactive (S/NS) antibodies indicated below. 
p-values are in comparison to antibodies of the corresponding Jκ group 
from healthy controls. (B) Vκ genes were divided into four groups accord-
ing to their 5′ to 3′ orientation in the Igκ locus (VκA–VκD). The propor-
tion of self-reactive antibodies in each Vκ group for healthy controls 
(references 1 and 7), SLE patients before treatment (reference 2), or SLE 
patients in clinical remission is indicated.2260  PERSISTANT AUTOANTIBODIES IN SLE REMISSION | Yurasov et al. 
self-reactive antibodies in active patients, but not in remission 
(Fig. 3 B; P = 0.003 and 0.052, respectively; references 1 and 2). 
In summary, mature naive B cells from SLE patients with active 
disease express self-reactive antibodies that are biased to contain 
3′ Vκ’s in association with 5′ Jκ’s, whereas those from patients 
in remission do not. Such antibodies are more likely to origi-
nate from primary rearrangements (13–15), suggesting that 
  active SLE is associated with increased expression of unedited 
self-reactive antibodies by mature naive B cells.
B cell tolerance is regulated by distinct checkpoints in the 
bone marrow and in the periphery. Either of these might be 
altered in SLE (for review see reference 18). Elegant studies 
with transgenic mice have demonstrated that nascent self-
  reactive B cells can be regulated by receptor editing, deletion, 
or anergy, and that receptor editing appears to be the  preferred 
mechanism to establish early B cell self-tolerance (13, 14, 19). 
Consistent with the primary importance of editing in shaping 
the B cell repertoire, this mechanism produces 25–50% of all 
antibodies (20, 21). In patients with active SLE or rheuma-
toid arthritis, and in mice with chronic autoimmune disease, 
the increase in self-reactive antibodies is consistent with 
  abnormalities in editing and/or selection (16, 17, 22). In SLE 
patients in clinical remission, normalization of Igκ gene usage 
is consistent with an overall decrease in the number of 
self-reactive antibodies in these patients.
Less is known about how B cell tolerance is established in 
the periphery. Both positive and negative selection mecha-
nisms have been proposed (18), and several genetic loci have 
been implicated in disease etiology (23). Under normal con-
ditions, one important determinant appears to be decreased 
expression of BAFF receptor on autoreactive B cells render-
ing them less able to compete for limiting amounts of BAFF, 
which is a key B cell survival factor (24). Consistent with this 
idea, excess BAFF expression leads to autoimmunity in mice 
(25–27), and patients with SLE show high levels of BAFF 
that could enable self-reactive B cells to survive in the mature 
naive B cell repertoire (28).
In conclusion, patients with SLE have increased numbers of 
circulating mature naive B cells that express self-reactive and 
polyreactive antibodies regardless of disease status. We speculate 
that these cells may increase disease susceptibility by serving as 
precursors for cells that produce pathogenic lupus antibodies.
MATERIALS AND METHODS
Patient samples and single B cell sorting. The study was performed in 
accordance with institutional review board–reviewed protocols of the UT 
Southwestern Medical Center (IRB no. 0199-017) and the Rockefeller 
University (SYU-0571-1005), and all samples were obtained after signed 
  informed consent at the Division of Pediatric Rheumatology of UT South-
western Medical Center. Control data and data from SLE100, SLE101, and 
SLE122 before treatment were previously published and are shown for direct 
comparison. Single B cell isolation was performed as described previously 
(1, 2, 7).
PCR amplifi  cation and expression vector cloning. Single cell cDNA 
synthesis and RT-PCR reactions were performed as described previously 
(1, 2, 7). All sequences matched published germline sequences of human Ig 
genes or could be attributed to polymorphisms (not depicted).
Antibody production, ELISA, and indirect immunofl  uorescence 
  assay. Antibodies were expressed in vitro as described previously (1, 2, 7). 
Antibody concentrations were determined by ELISA (1, 2, 7). ELISAs were 
performed as described previously (1, 2, 7), and dilutions are indicated in the 
fi  gures. Samples from SLE patients were considered negative if the OD405 
did not exceed a threshold value as indicated in each graph at any of the four 
dilutions in at least three independent experiments (Tables S1–S6). Thresh-
old values for reactivity with specifi  c antigens were set in all assays using 
  antibodies from healthy donors and included our previously published con-
trol antibodies, mGO53 (negative), eiJB40 (low positive), and ED38 (strong 
  positive; references 1 and 29). HEp-2 ELISAs were performed as described 
previously (1, 2, 7). The threshold OD405 levels below which samples were 
considered negative are indicated in the graphs. Positive and negative 
  controls included sera from patients and healthy individuals (INOVA 
  Diagnostics) and were included in every experiment.
Indirect immunofl  uorescence assays were performed as described previ-
ously (1). Controls included ED38 (1) and positive and negative sera 
(Bion Enterprises, Ltd.).
Statistics. p-values for Ig gene repertoire analyses, analysis of positive 
charges in IgH CDR3, and antibody reactivity were calculated by 2 × 2 or 
2 × 5 Fisher’s Exact test or Chi-square test. p-values for IgH CDR3 length 
were calculated by Student’s t test.
Online supplemental material. Fig. S1 shows representative FACS profi  les 
of B cells from SLE patients in clinical remission. Fig. S2 shows antibody stain-
ing patterns in HEp-2 cell immunofl  uorescence assay. Tables S1–S6 show IgH 
and IgL chain characteristics and antibody reactivity for mature naive B cells 
of SLE patients in clinical remission. The online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20061446/DC1.
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